Monoclonal Gammopathy of Renal Significance: New Capabilities of Therapy

Abstract

Objective of the Review: To draw attention to the new capabilities of the therapy of patients with monoclonal gammopathy of renal significance (MGRS). Key Points. The article analyses and systematises available information on possible therapies of MGRS. This condition adversely affects the quality of a patient’s life, causes renal parenchyma dysfunction and terminal chronic kidney disease. Special attention is paid to cooperation between hematologists and nephrologists in management of such patients. We describe the capabilities of the modern cloneoriented therapy, advantages and disadvantages of chemotherapeutic agents used. Conclusion. Currently, the preferred approach to management of patients with MGRS is close cooperation between hematologists and nephrologists in order to personalize therapy taking into account clinical course of the disease and concomitant pathologies. Keywords: monoclonal gammopathy of renal significance, clone-oriented therapy, monoclonal protein.